Trials / Completed
CompletedNCT00051675
Phase I Study of a Monoclonal Antibody for Treatment of Advanced Adenocarcinomas
An Open-Label, Multi-Dose, Phase I, Dose-Escalating Study of a Subcutaneously Administered Human-Engineered Monoclonal Antibody, ING-1(heMAb), in Subjects With Advanced Adenocarcinomas
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (planned)
- Sponsor
- XOMA (US) LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety, immunogenicity, and tolerability of a monoclonal antibody administered subcutaneously in the treatment of advanced cancers of the ovary, breast, lung, prostate, colon or rectum that are either refractory to standard therapies or for which therapies that may potentially be of major benefit do not exist.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ING-1(heMAb) |
Timeline
- Start date
- 2002-07-01
- Completion
- 2003-09-01
- First posted
- 2003-01-16
- Last updated
- 2005-06-24
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00051675. Inclusion in this directory is not an endorsement.